$ACST well, delaying the results to seek FDA input and guidance parallel to analyzing the T2 data and then presenting them all in Q3 2020 is probably the most logical and coherent thing to do at this point. It hurts, yes. But it is certainly better than to see a failed drug. I think the company is being transparent with their intentions and don’t want give up. At least that’s what I got from this morning’s release.